NASDAQ: APGE - Apogee Therapeutics, Inc. Common Stock

Yield per half year: -36.92%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Apogee Therapeutics, Inc. Common Stock

Extended chart Simple chart
Financial Markets by TradingView

About Apogee Therapeutics, Inc. Common Stock

Apogee Therapeutics, Inc. через свою дочернюю компанию работает как биотехнологическая компания, разрабатывающая биологические препараты для лечения атопического дерматита (АД), хронической обструктивной болезни легких (ХОБЛ) и связанных с ними воспалительных и иммунологических заболеваний. В первую очередь компания разрабатывает APG777, подкожное (SQ) моноклональное антитело (mAb) с увеличенным периодом полувыведения для лечения БА; и APG808, mAb с увеличенным периодом полувыведения SQ для лечения ХОБЛ.

more details
Его программы более ранней стадии включают APG990, mAb SQ с увеличенным периодом полужизни для лечения AD; и APG222, SQ антитела с увеличенным периодом полужизни для AD. Компания была основана в 2022 году и базируется в Уолтеме, штат Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2023-07-14
ISIN US03770N1019
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.apogeetherapeutics.com
Цена ао 31.08
Change price per day: 0% (30.53)
Change price per week: -11.64% (34.55)
Change price per month: -24.28% (40.32)
Change price per 3 month: -32.38% (45.15)
Change price per half year: -36.92% (48.4)
Change price per year: -18.02% (37.24)
Change price per 3 year: 0% (30.53)
Change price per 5 year: 0% (30.53)
Change price per 10 year: 0% (30.53)
Change price per year to date: -32.6% (45.3)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 4.14 4
P/E 0 0
EV/EBITDA -15.67 0
Total: 2.25

Efficiency

Title Value Grade
ROA, % -20.92 0
ROE, % -22.11 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0219 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 173.33 10
Yield EPS, % 111.17 10
Total: 8
More

Institutions Volume Share, %
VR Adviser, LLC 8493321 14.53
FMR, LLC 5018880 8.59
Fairmount Funds Management LLC 2941176 5.03
Deep Track Capital, LP 2323456 3.98
RTW Investments LP 2142591 3.67
RA Capital Management, L.P. 1977901 3.38
Perceptive Advisors LLC 1827901 3.13
Blackrock Inc. 1644037 2.81
Wellington Management Group, LLP 1591478 2.72
Driehaus Capital Management, LLC 1329064 2.27

ETF Share, % Profitability for 1 year, % Dividends, %
Future Tech ETF 0.25491 426.34 0.8416
Principal Healthcare Innovators ETF 0.25491 618.5 0.8416
iShares Russell 2000 Growth ETF 0.16363 38.04 0.6026
iShares ESG Aware MSCI USA Small-Cap ETF 0.05776 18.09 1.49366
iShares Morningstar Small-Cap ETF 0.02703 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.02703 391.25 1.60498
iShares Russell 3000 ETF 0.00435 24.83 1.43482



Head Job title Payment Year of birth
Dr. Michael Thomas Henderson M.D. CEO & Director 1.17M 1989 (36 years)
Dr. Carl Linden Dambkowski M.D. Chief Medical Officer 870.83k 1985 (40 years)
Ms. Jane Pritchett V. Henderson Chief Financial Officer 843.64k 1966 (59 years)
Dr. Rebecca Dabora Ph.D. Chief Development Officer N/A 1960 (65 years)
Ms. Noel Kurdi Vice President of Investor Relations N/A
Mr. Matthew Batters J.D. Chief Legal Officer & Corporate Secretary N/A 1976 (49 years)
Ms. Emily Cox VP & Head of People N/A
Ms. Wendy Aspden-Curran Senior Vice President of Clinical Operations N/A
Dr. Drew Badger Ph.D. Senior VP and Head of Regulatory Affairs & Toxicology N/A
Ms. Monica Forbes Senior Vice President of Finance N/A 1976 (49 years)

Address: United States, Waltham. MA, 221 Crescent Street - open in Google maps, open in Yandex maps
Website: https://www.apogeetherapeutics.com